To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
- X. Liu
- dinsdag 15 februari 2022
2311 GJ Leiden
- Prof.dr. A.P. IJzerman
- Prof.dr. G.J.P. van Westen
- Prof dr. Kai Ye (Xi'An Jiaotong University)
Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods have attracted particular interest in drug design.
In this study, a new deep learning-based method (DrugEx) was proposed to design de novo drug-like molecules. It was proven that candidate molecules designed by DrugEx had a larger chemical diversity, and better covered the chemical space of known ligands. In order to address the issue of polypharmacology, the DrugEx algorithm was updated with multi-objective optimization towards multiple targets. The results of its application demonstrated the generation of compounds with a diverse predicted selectivity profile toward multiple targets, offering the potential of high efficacy and lower toxicity.
In order to improve its generality, DrugEx was further updated to have the capability of designing molecules based on given scaffolds. We extended the architecture of Transformer to deal with each molecule as a graph. As a proof, its effectiveness in that 100% valid molecules are generated and most of them had predicted high affinity towards A2AAR with given scaffolds.
Moreover, GenUI was developed as a visualizion software platform that makes it possible to integrate molecular generators within a feature-rich graphical user interface to facilitate collaboration in the disparate communities interested in computer-aided drug discovery.
These studies highlight the overwhelming power of AI methods in drug discovery.
Proefschriften van Leidse promovendi zijn na de promotie digitaal beschikbaar via het Leids Repositorium. De proefschriften op deze site zijn vrij toegankelijk. Alleen in sommige gevallen rust er een tijdelijk embargo op een proefschrift en wordt het proefschrift pas later volledig beschikbaar gesteld.
Persvragen (alleen journalisten)
071 527 1521
071 527 7211